An in-vitro model for tumor immunotherapy with antibody heteroconjugates
1988; Elsevier BV; Volume: 9; Issue: 9 Linguagem: Inglês
10.1016/0167-5699(88)91304-7
ISSN1355-8242
AutoresGundram Jung, H J Muller Eberhard,
Tópico(s)CAR-T cell therapy research
ResumoThe use of monoclonal antibodies in cancer therapy has been largely unsuccessful in producing long-term therapeutic effects. In this article, Gundram Jung and Hans Müller Eberhard describe an in-vitro model in which two different antibody heteroconjugates (AHCs), employed jointly, activate resting human T cells on the surface of tumor cells. Activation is independent of accessory cells and proceeds in the presence of human serum. Once activated, the T cells destroy the tumor cells that provided the surface for their AHC-induced activation. These results suggest that certain AHCs may both induce and mediate T-cell cytotoxicity on the surface of tumor cells in vivo. This model provides the rationale for the combined in-vivo use of the two AHCs.
Referência(s)